Polyclonal Antibody to Growth Regulated Oncogene Gamma (GROg)
| Code | Size | Price |
|---|
| PAB604Hu01-20ul | 20ul | £84.00 |
Quantity:
| PAB604Hu01-100ul | 100ul | £155.00 |
Quantity:
| PAB604Hu01-200ul | 200ul | £208.00 |
Quantity:
| PAB604Hu01-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GROg; SCYB3; GRO3; GRO-G; MIP2-B; MIP2b; CINC2b; CINC2b; Growth Regulated Oncogene Gamma; Macrophage inflammatory protein 2-beta
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Chemokine (C-X-C Motif) Ligand 3
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/31810929;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Growth Regulated Oncogene Gamma (GROg) | RPB604Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||